Diagnostic methods for determining prognosis of non-small cell lung cancer

US8951725B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Larry E. Morrison · Glen Ellyn, US
• John Coon · Oak Park, US

Key dates

• Filing date: Apr 14, 2008
• Grant date: Feb 10, 2015
• Expiry date: Apr 14, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/118
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combin…